PRGO

Perrigo Company PLC
NYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$2.06B
P/E Ratio
EPS
$-12.29
Beta
0.60
52W High
$20.70
52W Low
$8.81
50-Day MA
$11.94
200-Day MA
$12.20
Dividend Yield
8.13%
Profit Margin
-41.80%
Forward P/E
6.15
PEG Ratio
1.14

About Perrigo Company PLC

Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$4.14B
Gross Profit (TTM)$1.38B
EBITDA$615.50M
Operating Margin3.84%
Return on Equity-48.70%
Return on Assets1.97%
Revenue/Share (TTM)$29.83
Book Value$18.14
Price-to-Book0.79
Price-to-Sales (TTM)0.50
EV/Revenue1.176
EV/EBITDA10.21
Quarterly Earnings Growth (YoY)-63.60%
Quarterly Revenue Growth (YoY)-3.20%
Shares Outstanding$138.37M
Float$138.08M
% Insiders0.40%
% Institutions120.65%

Historical Volatility

HV 10-Day
34.23%
HV 20-Day
39.85%
HV 30-Day
71.46%
HV 60-Day
64.15%
HV Rank
79.8%

Volatility is currently contracting

Analyst Ratings

Consensus ($16.50 target)
1
Strong Buy
1
Buy
3
Hold

Latest News

Perrigo to Attend the Barclays Global Consumer Conference

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026.  About Perrigo    Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.

PRNewsWire8/27/2026Neutral
PRGO or NEOG: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Zacks Investment Research8/26/2026Positive
Should Value Investors Buy Perrigo (PRGO) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research8/26/2026Positive
My Top 5 Dividend Picks For August

I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.

Seeking Alpha8/24/2026Positive
Perrigo: The Rebound Is Just Getting Started

Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

Seeking Alpha8/13/2026Positive
PRGO vs. NEOG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research8/10/2026Positive
Are Investors Undervaluing Perrigo (PRGO) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research8/10/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRGO and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026